Michael Drummond PhD
Professor of Health Economics
University of York, Heslington, York, UK

HOW SHOULD THE MEDIA CONVEY INFORMATION ABOUT NEW MEDICAL TECHNOLOGIES?

Speakers:

Drummond Rennie, MD, FRCP, MACP, Deputy Editor (West), Journal of the American Medical Association & Adj. Prof Medicine, Institute for Health Policy Studies, University of California San Francisco, Jacksonville, OR, USA
Snigdha Prakash, Reporter, NPR®, Washington DC, USA (photo credit: Debbie Accame )
Professor Peter Littlejohns, Clinical and Public Health Director, National Institute for Health and Clinical Excellence (NICE)

The media is now a prevalent and effective means for creating knowledge of and demand for new medical technologies. What patients demand after seeing advertisements and news stories on new products may conflict with what outcomes researchers feel is effective or cost-effective use of those technologies. This session will explore the media's role in the adoption and use of medical technologies, and what might constitute the ideal media message template for reports on new drugs and devices.
 

Podium Session I: Health Care Decisions Using Outcomes Research Information Case Studies I *New*

The objective of these case studies is to provide an opportunity for individuals making health care decisions to show how cost and outcomes research studies were used or, perhaps, not used. These case studies describe situations where organizations attempted to integrate cost and outcome information to their processes and procedures for pharmaceuticals.

Case Studies

CASE 1 
REVIEWING THE REIMBURSEMENT STATUS OF PHARMACEUTICALS – EXPERIENCES FROM SWEDEN
Engstrom A, Ramsberg J,
Pharmaceutical Benefits Board, Solna, Sweden

CASE 2
COST CONTROL FOR MENTAL HEALTH
Dubberly J¹, Perri M², Smith L¹, Walthour A^2
1The Georgia Department of Community Health, Atlanta, GA, USA, ²University of Georgia, Athens, GA, USA

CASE 3
APPLICATION OF COST-EFFECTIVENESS ANALYSIS TO EVALUATE THE PROPOSED FORMULARY STATUS OF A NOVEL ANTIDIABETIC DRUG IN A U.S. COMMERCIAL HEALTH PLAN
Watkins J¹, Minshall M², Sullivan S^3
1Premera Blue Cross, Mountlake Terrace, WA, USA, ²IMS-Health, Noblesville, IN, USA, ³University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA

Podium Session I: Arthritis

AR1
COST-EFFECTIVENESS OF ETANERCEPT AND INFLIXIMAB IN THE REAL-WORLD SETTING – AN ESTIMATE BASED ON PUBLISHED GERMAN DATA ON RESPONSE AND ADHERENCE
Ekelund M¹, Deeg M², Runge C^2
1Wyeth AB, Solna, Sweden, ²Wyeth Pharma GmbH, Münster, Germany

AR2
THE ASSOCIATION BETWEEN CO-EXISTING IMMUNE MEDIATED INFLAMMATORY DISEASES (IMID) AND HEALTHCARE COSTS IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) WHO RECEIVED ANTI-TUMOR NECROSIS FACTORS (ANTI-TNFS)
Tang B¹, Rahman M¹, Stephenson J², Quimbo R², Dabbous O¹, Thompson H^1
1Centocor, Inc, Horsham, PA, USA, ²HealthCore, Inc, Wilmington, DE, USA

AR3
CAUSES AND EFFECTS OF SCENARIO REJECTION: STATED PREFERENCES FOR RHEUMATOID ARTHRITIS TREATMENTS
Ozdemir S¹, Johnson FR¹, Hauber B², Bala M^3
1Research Triangle Institute, Research Triangle Park, NC, USA, ²Research Triangle Institute, Doylestown, PA, USA, ³Johnson & Johnson, Malvern, PA, USA

AR4
METHODS FOR MEASURING DOSE ESCALATION IN TNF ANTAGONISTS FOR RHEUMATOID ARTHRITIS PATIENTS TREATED IN ROUTINE CLINICAL PRACTICE
Gu NY¹, Huang X², Globe D², Fox KM^3
1University of Southern California, Los Angeles, CA, USA, ²Amgen, Thousand Oaks, CA, USA, ³University of Maryland School of Medicine, Monkton, MD, USA

Podium Session I: Cardiovascular Studies

CV1
IMPACT OF A TARGETED PATIENT COMMUNICATION ENCOURAGING GREATER GENERIC STATIN USE
Kulkarni AS, Cox E, Mager D
Express Scripts Inc, Maryland Heights, MO, USA

CV2
MEDICATION REFILL PERSISTENCE: DOES PRESCRIPTION COST-SHARING MATTER?
Zhang D¹, Carlson AM², Gleason PP³, Schondelmeyer SW⁴, Schommer JC⁴, Dowd BE⁴, Heaton AH^5
1IMS Health, Blue Bell, PA, USA, ²Data Intelligence Consultants LLC, Eden Prairie, MN, USA, ³Prime Therapeutics LLC, Eagan, MN, USA, ⁴University of Minnesota, Minneapolis, MN, USA, ⁵BlueCross BlueShield of Minnesota, Eagan, MN, USA

CV3
LONG-TERM HEALTH OUTCOMES FOR PATIENTS HOSPITALIZED WITH UNSTABLE ANGINA AND NSTEMI IN THE CALIFORNIA MEDICAID POPULATION: ASSESSMENT OF CLOPIDOGREL THERAPY IN ACS
Vo P¹, Hauch O², Nichol MB¹, Borok GM², Dow T¹, Levinson JD^2
1University of Southern California, Los Angeles, CA, USA, ²AstraZeneca LP, Wilmington, DE, USA

CV4
THE IMPACT OF A CALCIUM CHANNEL BLOCKER PREFERRED DRUG LIST ON MEDICAID PRESCRIPTION EXPENDITURES AND UTILIZATION.
Martin BC, Pathak P, Helm M
University of Arkansas for Medical Sciences, Little Rock, AR, USA

Podium Session I: Medicare Part D

MD1
WHAT IF THE FEDERAL SUPPLY SCHEDULE SET PHARMACEUTICAL PRICES FOR SENIORS?
Gellad WF¹, Schneeweiss S², Brawarsky P¹, Haas JS^1
1Brigham and Women's Hospital, Boston, MA, USA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

MD2
PER-PATIENT-PER-MONTH DRUG COSTS IN MEDICARE PART D PROTECTED CLASSES
Mucha L¹, Axelsen K², Masia N^3
1Thomson Medstat, Cambridge, MA, USA, ²Pfizer Global Pharmaceuticals, New York, NY, USA, ³Pfizer Inc, New York, NY, USA

MD3
CHANGES IN PRESCRIPTION USE AND OUT-OF POCKET COSTSAMONG MEDICARE ELIGIBLE ADULTS, 2005-2006
Yin W¹, Basu A¹, Zhang JX¹, Sun SX², Lee KY², Meltzer DO¹, Alexander GC^1
1University of Chicago, Chicago, IL, USA, ²Walgreens Health Services, Deerfield, IL, USA

MD4
MEDICAID PREFERRED DRUG LISTS' COSTS TO PHYSICIANS
Ketcham JD¹, Epstein AJ^2
1Arizona State University, Tempe, AZ, USA, ²Yale University, New Haven, CT, USA

Podium Session I: Women's Health

WH1
BREAST CANCER PATIENTS' PREFERENCES FOR LOCAL AND SYSTEMIC THERAPY
Cooke JL¹, Mullins CD², Tkaczuk K³, Baquet CR^4
1Xavier University - Louisiana College of Pharmacy, New Orleans, LA, USA, ²University of Maryland School of Pharmacy, Baltimore, MD, USA, ³University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA, ⁴University of Maryland School of Medicine, Baltimore, MD, USA

WH2
STANDARD GAMBLE TECHNIQUES FOR THE MEASUREMENT OF TREATMENT RELATED TOXICITY IN ONCOLOGY: APPLICATION TO BREAST CANCER
Simons WR
Global Health Economics & Outcomes Research, Inc, Summit, NJ, USA

WH3
REDUCED WORK LIMITATION WITH IMPROVEMENT IN MOOD, SLEEP AND VASOMOTOR SYMPTOMS IN POSTMENOPAUSAL WOMEN
Bobula JD, Yu H, Olivier S
Wyeth Research, Collegeville, PA, USA

WH4
ECONOMIC EVALUATION OF FEMALE VACCINATION WITH A QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE IN NEW ZEALAND
Milne RJ¹, Vander Hoorn S¹, Kulasingam S², Tan AL^3
1University of Auckland, Auckland, New Zealand, ²Duke University, Durham, NC, USA, ³Auckland District Health Board, Auckland, New Zealand
 

QUALITY OF LIFE / PATIENT-REPORTED OUTCOMES STUDY METHODOLOGY ISSUES

IP1: MEETING PROPOSED FDA STANDARDS FOR PATIENT-REPORTED OUTCOMES (PROS): ARE THEY ACHIEVABLE?

Moderator: Paul Langley, PhD, Director, Maimon Research LLC, Tucson, AZ, USA; Adjunct Professor, College of Pharmacy, University of Minnesota, USA
Panelist(s): Lynda Doward, MRes, Associate Director of Research, Galen Research, Manchester, UK; David Meads, MSc, Research Associate, Galen Research, Manchester, UK

USE OF HEALTH ECONOMIC / PHARMACOECONOMIC INFORMATION BY DECISION MAKERS ISSUES

IP2: SHOULD THERE BE DIFFERENT CRITERIA FOR ASSESSING ORPHAN DRUGS?

Moderator: Peter J. Neumann, ScD, Professor, Tufts University School of Medicine, Boston, MA, USA
Panelist(s): David Wilson, MA, Director Health Economics, Genzyme Corporation, Cambridge, MA, USA; Mike F. Drummond, PhD, Professor, University of York, York, UK; Peter Littlejohns, MD, Clinical and Public Health Director, National Institute for Health and Clinical Excellence, London, UK

MEDICAL DEVICE, DIAGNOSTICS AND BIOTECHNOLOGY ISSUES

IP3: TECHNOLOGY ASSESSMENT OF MEDICAL DEVICES: IS IT DIFFERENT?

Moderator: Gary M. Franklin, MD, MPH, Research Professor, University of Washington, Seattle, WA; Medical Director, Washington State Department of Labor and Industries, Olympia, WA.
Panelist(s): Peter Juhn, MD, MPH, Executive Medical Director, Health Policy and Evidence-based Medicine, Johnson and Johnson Corporate, New Brunswick, NJ; Steve Phurrough, MD MPA, Director, Coverage and Analysis Group, Office of Clinical Standards and Quality, Center for Medicare and Medicaid Services, Baltimore, MD

CLINICAL OUTCOMES/TREATMENT GUIDELINES ISSUES

IP4: USING REAL WORLD DATA IN COST-EFFECTIVENESS ANALYSIS?

Moderator: Alistair McGuire PhD, Professor in Health Economics, London School of Economics, London, UK.
Panelist(s): William Crown, PhD, President, i3innovus, Waltham, MA, USA; John Cook, PhD, Merck & Co., North Wales, PA, USA

HEALTH CARE REIMBURSEMENT / COVERAGE ISSUES

IP5: THE ECONOMICS OF PERSONALIZED MEDICINE: CAN WE AFFORD IT?

Moderator: Deborah Marshall, PhD, Vice President, Global Health Economics and Outcomes Research, i3 Innovus, Burlington, ON, Canada.
Panelist(s): Ernst R. Berndt, PhD, Louis E. Seley Professor in Applied Economics MIT Sloan School of Management, Cambridge, MA; Scott Gottlieb, MD, Resident Fellow, American Enterprise Institute, Washington, DC; Jean Paul Gagnon, PhD, RPh, Director of Public Policy, sanofi-aventis, Bridgewater, NJ, USA; Jean Paul Gagnon, PhD, RPh, Director of Public Policy, sanofi-aventis, Bridgewater, NJ, USA

Raising the Bar in the U.S.: The Impact of Heightened Awareness of the Need for Health-Economic Data in the Absence of a Regulatory Mandate

Symposium Description:
This session will provide an overview of the changing environment for health-economic data in the U.S., including new payer-driven requirements, increased levels of dossier submissions, and heightened awareness of the inclusion of health-economic data in formulary decision-making.  A presentation also will be made that describes how this new awareness is incorporated into daily practice at one institution, including a review of the potential advantages and pitfalls of new approaches.

Symposium Speakers:

Jonothan C. Tierce, CPhil, Practice Leader, Health Economics and Outcomes Research, IMS Consulting, Falls Church, VA, USA 

Michael E. Minshall, MPH, Principal, Health Economics and Outcomes Research, IMS Health & Adjunct Professor, Indiana University School of Medicine, Department of Public Health, Noblesville, IN, USA

John Watkins, RPh, MPH, BCPS, Pharmacy Manager, Formulary Development, Premera Blue Cross, Seattle, WA, USA 

Podium Session II: Health Care Decisions Using Outcomes Research Information Case Studies II *New*

The objective of these case studies is to provide an opportunity for individuals making health care decisions to show how cost and outcomes research studies were used or, perhaps, not used. These case studies describe situations where organizations attempted to integrate cost and outcome information to their processes and procedures for pharmaceuticals.

Case Studies

CASE 4
IMPLEMENTATION AND EVALUATION OF AN EVIDENCE-BASED CONTINUUM FOR HIP AND KNEE REPLACEMENTS IN ALBERTA
Wasylak T¹, Lahey MS², McBain D³, Frank C⁴, Gooch K⁵, Hibbert J^6
1Calgary Health Region, Calgary, AB, Canada, ²Capital Health, Edmonton, AB, Canada, ³David Thompson Health Region, Red Deer, AB, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵Institute of Health Economics, Calgary, AB, Canada, ⁶Institute of Health Economics, Calgary, AB, Canada

CASE 5
OUTCOMES RESEARCH FOR MILITARY VACCINATION POLICY: THE US ARMY ACCESSION SCREENING AND IMMUNIZATION PROGRAM
Ford S¹, Hughes H¹, Nevin R^2
1Military Vaccine Agency, Falls Church, VA, USA, ²Army Medical Surveillance Activity, Silver Spring, MD, USA 

CASE 6
INCORPORATION OF COST EFFECTIVENESS FOR FORMULARY ADDITIONS AT A CANCER CENTER
Curry E, Arbuckle B
MD Anderson Cancer Center, Houston, TX, USA

Podium Session II: Medication Adherence & Outcomes

AO1
MEDICATION COMPLIANCE TO STATIN THERAPY AND ITS IMPACT ON DISEASE OUTCOMES IN TYPE 2 DIABETES
Zhang L, Nichol MB
University of Southern California, Los Angeles, CA, USA

AO2
THE ASSOCIATION BETWEEN THERAPEUTIC PERSISTENCE AND NON-PHARMACY COST AMONG ANTI-TUMOR NECROSIS FACTORS (ANTI-TNFS) IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Tang B¹, Thompson H¹, Meissner B², Dabbous O¹, Rahman M^1
1Centocor, Inc, Horsham, PA, USA, ²Xcenda, Palm Harbor, FL, USA

AO3
PERSISTENT USE OF ANTIHYPERTENSIVE DRUGS LEADS TO A TWO TIMES INCREASED CHANCE OF BLOOD PRESSURE GOAL ATTAINMENT IN STAGE 2 ANTIHYPERTENSIVE PATIENTS
Breekveldt-Postma NS¹, Siiskonen SJ¹, Penning-van Beest FJA¹, Erkens JA¹, Vincze G², Falvey H², Herings RMC^1
1PHARMO Institute, Utrecht, The Netherlands, ²Novartis Pharma AG, Basel, Switzerland

AO4
ADHERENCE TO GASTROPROTECTION AND THE RISK OF NSAID-RELATED UPPER GASTROINTESTINAL COMPLICATIONS
Van Soest E, Sturkenboom MC, Dieleman JP, Verhamme K, Siersema PD, Kuipers E
Erasmus University Medical Center, Rotterdam, The Netherlands

Podium Session II: Methods & Concepts

MC1
METHODS OF MODEL CALIBRATION: A COMPARATIVE APPROACH
Taylor DC¹, Kruzikas D², Pandya A¹, Iskandar R¹, Gilmore K¹, Weinstein MC^3
1i3 Innovus, Medford, MA, USA, ²GlaxoSmithKline, Philadelphia, PA, USA, ³Harvard University, Boston, MA, USA

MC2
COMPARISON OF TRADITIONAL MULTIVARIABLE LOGISTIC REGRESSION AND PROPENSITY SCORE APPROACHES FOR CONTROLLING FOR TREATMENT SELECTION BIAS USING MONTE CARLO SIMULATION
Wang J, Wu Y, Irish WD
RTI Health Solutions, Research Triangle Park, NC, USA

MC3
CONTROLLING FOR COMORBIDITIES USING VARIATIONS OF THE CHARLSON COMORBIDITY INDEX ON MEDICARE CLAIMS DATA: THE CASE OF OVERACTIVE BLADDER
Cisternas MG, Foreman AJ, Miller DP
Ovation Research Group, San Francisco, CA, USA

MC4
TIME HORIZON BIAS IN ECONOMIC EVALUATIONS
Sander B¹, Krahn MD^2
1University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada

Podium Session II: Neurology

NE1
MEDICAL COMORBIDITIES, PHARMACEUTICAL USE AND HEALTH CARE COSTS IN PATIENTS WITH FIBROMYALGIA
White LA¹, Birnbaum HG¹, Kaltenboeck A¹, Tang J¹, Robinson RL^2
1Analysis Group, Inc, Boston, MA, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

NE2
IMPACT OF PATIENT COMORBIDITIES ON PHARMACOLOGICAL TREATMENT OF INSOMNIA: AN ANALYSIS OF THE NATIONAL AMBULATORY MEDICAL CARE SURVEY DATA: 1995-2004
Pawaskar MD, Balkrishnan R
The Ohio State University College of Pharmacy, Columbus, OH, USA

NE3
THE IMPORTANCE OF MODIFYING THE COURSE OF ALZHEIMER'S DISEASE: OLDER AMERICANS' RISK-BENEFIT PREFERENCES FOR NEW TREATMENTS
Mohamed AF¹, Johnson FR¹, Hauber B², Leibman C³, Arrighi HM^3
1Research Triangle Institute, Research Triangle Park, NC, USA, ²Research Triangle Institute, Doylestown, PA, USA, ³Elan Pharmaceuticals, Inc, San Diego, CA, USA

NE4
COST-UTILITY ANALYSIS EVALUATING LIDOCAINE 5% MEDICATED PLASTER RELATIVE TO GABAPENTIN FOR POST-HERPETIC NEURALGIA IN SCOTLAND
Dakin HA¹, Nuijten MJC², Liedgens H³, Poulsen Nautrup B^3
1Abacus International, Bicester, Oxfordshire, UK, ²Erasmus University, Rotterdam, The Netherlands, ³Grünenthal GmbH, Aachen, Germany

Podium Session II: Respiratory Disorders

RS1
COST EFFECTIVENESS OF QUANTIFERON IN SCREENING FOR TUBERCULOSIS INFECTION IN CLOSE CONTACTS IN JAPAN
Kowada A¹, Takahashi O², Shimbo T³, Tokuda Y², Ohde S², Yanai H⁴, Rahman M⁵, Fukui T^2
1Kanamachi Public Health Center, Tokyo, Japan, ²St. Luke's Life Science Institute, Chuo, Tokyo, Japan, ³International Medical Center of Japan, Shinjyuku-ku, Tokyo, Japan, ⁴St. Luke's School of Nursing, Chuo, Tokyo, Japan, ⁵Marshfield Epidemiology Research Center, Marshfield, WI, USA

RS2
INCREMENTAL COSTS ASSOCIATED WITH ANTIBIOTICS PRESCRIBED FOR COMMUNITY ACQUIRED PNEUMONIA
Asche C¹, Mucha L², Lenhart G³, Seal B^4
1University of Utah, Salt Lake City, UT, USA, ²Thomson Healthcare: Medstat, Cambridge, MA, USA, ³Thomson Medstat, Cambridge, MA, USA, ⁴Sanofi-Aventis, Bridgewater, NJ, USA

RS3
THE HEALTH STATUS BURDEN OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN A U.S. MEDICARE POPULATION: FINDINGS FROM THE MEDICARE CURRENT BENEFICIARY SURVEY
Menzin J¹, Dastani H², Guadagno L¹, Dirani RG³, Marton JP³, Phillips AL², Shah H^2
1Boston Health Economics, Inc, Waltham, MA, USA, ²Boehringer-Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA, ³Pfizer Global Pharmaceuticals, Pfizer Inc, New York, NY, USA

RS4
IMPACT OF EARLY INITIATION OF INHALED CORTICOSTEROIDS ON RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH COPD: A PROPENSITY SCORE MATCHING APPROACH
Akazawa M, Stearns S, Biddle AK
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

ISPOR STUDENT FORUM

WRITING MANUSCRIPTS THAT WILL GET THROUGH THE PEER-REVIEW PROCESS: ADVICE FROM THE EDITOR-IN-CHIEF OF VALUE IN HEALTH
Moderator: Zeba Khan PhD, Executive Director, Pricing, General Medicines, Novartis Pharmaceuticals, and East Hanover, NJ, USA
Speakers: Josephine Mauskopf PhD, Global Head, Health Economics and Outcomes Strategy, RTI Health Solutions, Research Triangle Park, NC, USA; C. Daniel Mullins PhD, Professor and Chair of Pharmaceutical Health Services Research, University of Maryland, School of Pharmacy, Baltimore, MD, USA

When you have successfully completed your dissertation or research assistant activities it is important to get the results into the public domain through peer-reviewed publications. The process for translating your findings into a published article can be daunting, which is why sometimes good research never gets published. Learn from the editor-in-chief and a co-editor of Value in Health how to increase the likelihood of publication by making sure that the methods used in your research are appropriate for your research question, carefully choosing the target journal, following good writing practice, and understanding the peer-review process.

ISPOR SPECIAL INTEREST GROUP FORUMS

ASSESSMENT, COSTS & DETERMINANTS OF MEDICATION COMPLIANCE & PERSISTENCE: ISPOR MEDICATION COMPLIANCE & PERSISTENCE SIG FORUM
Moderator: Joyce Cramer BS, ISPOR Medication Compliance & Persistence SIG Chair & Research Scientist, Yale University School of Medicine, West Haven, CT, USA

3:15-3:20 Introduction

3:20-3.35 Medication Compliance & Persistence Assessment in Prospective Research
Speaker: Kristina Yu-Isenberg, PhD, MPH, RPh, ISPOR Analyses Standards Leadership Group & Director, Business Development, GlaxoSmithKline, Research Triangle Park, NC, USA

Critically appraising articles that involve compliance research requires an understanding about the best methodology to conduct trials within a number of study settings such as:  randomized controlled clinical trials setting, observational cohort, and quasi-experimental.  Key considerations for researchers regarding the design, analysis and reporting of results of such trials will be reviewed.

3:35-3.50 The Costs of Noncompliance
Speaker: Dyfrig Hughes PhD, MSc, ISPOR Economics of Compliance & Persistence Working Group Chair & Senior Research Fellow in Pharmacoeconomics, University of Wales, Bangor, North Wales, UK

Medication non-compliance and failure to persist with chronic treatments have substantial economic consequences.  A systematic review will provide an evidence-based estimate of overall costs for selected diseases (osteoporosis and diabetes).

3.50-4.05 Determinants of Compliance & Persistence
Speaker: Femida Gwadry-Sridhar PhD, RPh, MSc, ISPOR Determinants of Compliance & Persistence Working Group Chair & Assistant Professor, University of Western Ontario & Mc Master University, Director CCR-Net & Director LHR Institute, London, ON, Canada

Interventions aimed at improving compliance often are not adequately targeted at key "determinants".  A systematic approach to match interventions to selected populations will improve the likelihood of achieving a positive effect.

4.05-4.15 Discussion

ISPOR PATIENT-REPORTED OUTCOMES GOOD RESEARCH PRACTICES

PUTTING THE “O” BACK IN ISPOR

Description: Recently, in the US, the FDA issued a draft Guidance for the Industry on Patient-Reported Outcome (PRO) Measures and, in Europe, EMEA issued a Reflection Paper on the Regulatory Guidance for the Use of Health Related Quality of Life Measures in the Evaluation of Medicinal Products. ISPOR members have identified a need for clarity on PRO measurements. In response, ISPOR initiated 3 PRO Task Forces (TFs) on the use and modification of existing instruments and instrument language change and administration change. The ISPOR PRO Task Force Chairs will discuss issues and concerns in the development of PRO good research practices documents.

Moderators: Donald Patrick PhD , ISPOR Health Science Policy Council Member & Professor, University of Washington, Seattle, WA, USA & Patrick Marquis PhD Chair, ISPOR Patient Reported Outcomes SIG’s PRO / QOL Information in Regulatory & Health Care Decisions Working Group & Managing Director, MAPI Values, Boston, MA, USA

Use of Existing PRO Instruments and their Modification
Speaker: Margaret Rothman, PhD, Chair: Use of Existing PRO Instruments & their Modification TF and Executive Director, Health Economics, Johnson & Johnson, Raritan, NJ  

Changing Culture or Language of PRO Application
Speaker: Diane Wild MSc, Chair: Changing Culture/Language of PRO Instruments TF & Director, Oxford Outcomes, Cassington, Oxford, UK

Changing Mode of Administration of PRO Instruments, including ePRO
Stephen J. Coons PhD Chair, Changing Mode of PRO Instrument Administration/ePRO TF & Professor of Pharmacy and Public Health, University of Arizona, Tucson, AZ, USA

ISPOR DRUG COST STANDARDS TASK FORCE FORUM

HOW SHOULD DRUG COSTS BE MEASURED FOR RESEARCH AND POLICY? A DISCUSSION OF THE REPORT OF THE DRUG COST TASK FORCE
How should drug costs be measured and reported for use in cost effectiveness studies? How does this differ when considering different perspectives, including: international, Medicare, Medicaid and other government programs, third party payers, industry and societal?

Speaker: Joel W Hay PhD, Associate Professor, Pharmaceutical Economics & Policy, University of Southern California, Los Angeles, CA, USA
Speaker: Jim Smeeding RPh, MBA, President, JestaRx Group, Dallas, Texas, USA

Podium Session III: Cancer

CN1
A COST – EFFECTIVENESS ANALYSIS MODEL FOR THE SECOND LINE TREATMENT OF GASTROINTESTINAL STROMAL TUMOURS (GIST) IN MEXICO
Contrera-Hernandez I¹, Mould-Quevedo J², Salinas-Escudero G¹, Silva A¹, Tapia-Valencia J², Davila-Loaiza G², Garduño-Espinosa J^1
1Social Security Mexican Institute, Mexico City, Mexico, ²Pfizer Mexico, Mexico City, Mexico,

CN2
PHARMACOECONOMIC ANALYSIS OF CAPECITABINE IN ADJUVANT TREATMENT OF STAGE III COLON CANCER IN TAIWAN
Hsu TC¹, Chen HH², Chen LT³, Changchien CR⁴, Liu MC⁵, Wang HM⁶, Yang L^7
1Taipei Medical University, Taipei, Taiwan, ²Chang Guang Memorial Hospital, Kaohsiung Branch, Kaohsiung, Taiwan, ³National Health Research Institutes, Taipei, Taiwan, ⁴Chang Guang Memorial Hospital, Linkou Branch, Linkou, Taiwan, ⁵Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan, ⁶Taichung Veterans General Hospital, Taichung, Taiwan, ⁷Roche Products Ltd, Taipei, Taiwan

CN3
60-MONTH DATA FROM IRIS USED TO UPDATE ESTIMATES OF SURVIVAL AND COST-EFFECTIVENESS OF FIRST-LINE IMATINIB IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA
Reed SD, Anstrom KJ, Li Y, Schulman KA
Duke Clinical Research Institute, Durham, NC, USA

CN4
PSYCHOMETRIC VALIDATION OF A PATIENT SYMPTOM ASSESSMENT-LUNG CANCER (PSALC) INSTRUMENT FOR SMALL CELL LUNG CANCER (SCLC)
Chen L¹, Duh M¹, Antras L¹, Neary MP², O'Brien ME^3
1Analysis Group, Inc, Boston, MA, USA, ²GlaxoSmithKline, Collegeville, PA, USA, ³Royal Marsden Hospital, Sutton, UK

Podium Session III: Cost Studies

CS1
EPOETIN ALFA AND DARBEPOETIN ALFA DOSING TRENDS AND DRUG COSTS IN ELDERLY PRE-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS
Mody S¹, Padmanabhan V², Bookhart B¹, Mckenzie RS^1
1Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA, ²Ortho Biotech Products, L.P, Bridgewater, NJ, USA

CS2
OUTCOMES ASSOCIATED WITH THE USE OF THIAZOLIDINEDIONES AMONG MEDICARE BENEFICIARIES WITH TYPE II DIABETES – AN INSTRUMENTAL VARIABLE APPROACH
Fang G¹, Zuckerman IH¹, Stuart B¹, Brooks JM^2
1University of Maryland, Baltimore, MD, USA, ²The University of Iowa, Iowa City, IA, USA

CS3
HEALTHCARE EXPENDITURE AND PATIENT SATISFACTION: COST AND QUALITY FROM HEALTHCARE CONSUMERS' PERSPECTIVE
Fu AZ, Wang N
Cleveland Clinic, Cleveland, OH, USA

CS4
A METHODOLOGY FOR PROJECTING DISEASE PREVALENCE, TREATMENT, AND EXPENDITURES FOR THE US EMPLOYER-INSURED POPULATION
Chang S¹, Hansen LG², Marder WD^3
1Thomson Medstat, Washington, DC, USA, ²Thomson Medstat, Northwood, NH, USA, ³Thomson Medstat, Cambridge, MA, USA

Podium Session III: Mental Health

MH1
OUTCOMES ASSOCIATED WITH THE IMPLEMENTATION OF A DOSE OPTIMIZATION PROGRAM FOR ATYPICAL ANTIPSYCHOTIC MEDICATIONS IN A MANAGED CARE ORGANIZATION
Dunn JD¹, Cannon HE¹, Nelson JC², Olson BM^3
1SelectHealth Plans, Salt Lake City, UT, USA, ²Eli Lilly and Company, Indianapolis, IN, USA, ³Dymaxium Inc, Toronto, ON, Canada

MH2
COMPARISON OF HEALTH CARE COSTS AND HOSPITALIZATION DAYS OF ELDERLY MAJOR DEPRESSIVE DISORDER PATIENTS TREATED WITH ESCITALOPRAM AND OTHER ANTIDEPRESSANTS
Wu E¹, Yang E¹, Greenberg P¹, Erder MH², Yu AP¹, Buesing M^1
1Analysis Group, Inc, Boston, MA, USA, ²Forest Research Institute, Jersey City, NJ, USA

MH3
PREVALENCE OF LIVER DISEASES IN MEDICAID RECIPIENTS WITH SCHIZOPHRENIA
Wu JH¹, Dickson M², Durkin M¹, Canuso CM^3
1Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, ²University of South Carolina, College of Pharmacy, Columbia, SC, USA, ³Janssen Medical Affairs, LLC, Titusville, NJ, USA

MH4
MEASURING THE INFLUENCE OF MANAGED CARE ON ANTIDEPRESSANT UTILIZATION BY CHILDREN AND ADOLESCENTS WITH DEPRESSION
Newsom J
Boston University, Newton, MA, USA

Podium Session III: Patient-Reported Outcomes

PR1
ABILITY OF SF-36 AND EQ-5D TO DISCRIMINATE AMONG DISEASE ACTIVITY LEVELS IN LUPUS
Wilke CT¹, Jolly M², Block JA², Khandelwal S², Rodby R², Pickard AS^3
1University of Illinois at Chicago, Chicago, IL, USA, ²Rush University Medical Center, Chicago, IL, USA, ³College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA

PR2
PREDICTING DISEASE BURDEN IN EQ-5D US UNITS FROM SEVEN OTHER MEASUREMENT SYSTEMS (EQ-5D UK, HALEX, HUI MARK 2, HUI MARK 3, QWB-SA, SF-6D(12), SF-6D(36))
Hanmer J¹, Franks P², Fryback DG^1
1University of Wisconsin - Madison, Madison, WI, USA, ²University of California, Davis, Sacramento, Sacramento, CA, USA

PR3
PREFERENCE VALUES FOR HEALTH STATES ASSOCIATED WITH COLON CANCER AND ITS TREATMENT
Best JH¹, Garrison L¹, Hollingworth W¹, Ramsey SD², Veenstra DL^1
1University of Washington, Seattle, WA, USA, ²Fred Hutchinson Cancer Research Center, Seattle, WA, USA

PR4
VALUING CHILDREN'S HEALTH FOR ECONOMIC EVALUATIONS: THEORETICAL AND METHODOLOGICAL CONSIDERATIONS
Prosser L¹, Hammitt JK², Keren R^3
1Harvard Medical School, Boston, MA, USA, ²Harvard School of Public Health, Boston, MA, USA, ³Children's Hospital of Philadelphia, Philadelphia, PA, USA